Kiniksa Pharmaceuticals International PLC

KNSA

Company Profile

  • Business description

    Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

  • Contact

    23 Old Bond Street
    Floor 3
    LondonW1S 4PZ
    GBR

    T: +44 7814319100

    E: [email protected]

    https://www.kiniksa.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    315

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,963.5029.200.33%
CAC 407,806.1328.45-0.36%
DAX 4023,988.39229.11-0.95%
Dow JONES (US)44,895.126.80-0.02%
FTSE 1009,071.0149.30-0.54%
HKSE25,562.13173.780.68%
NASDAQ21,175.0366.720.32%
Nikkei 22540,998.27457.96-1.10%
NZX 50 Index12,910.7457.280.45%
S&P 5006,394.115.470.09%
S&P/ASX 2008,697.7030.800.36%
SSE Composite Index3,597.944.280.12%

Market Movers